Literature DB >> 9635847

High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.

M P Lyttelton1, E S Newlands, C Giles, M Bower, A Guimaraes, S O'Reilly, G J Rustin, D Samson, E J Kanfer.   

Abstract

Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9635847      PMCID： PMC2150058          DOI： 10.1038/bjc.1998.275

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  14 in total

1.  High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

Authors:  J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

2.  Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989).

Authors:  R J Motzer; N L Geller; C C Tan; H Herr; M Morse; W Fair; J Sheinfeld; P Sogani; P Russo; G J Bosl
Journal:  Cancer       Date:  1991-03-01       Impact factor: 6.860

3.  High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study.

Authors:  G Rosti; L Albertazzi; R Salvioni; G Pizzocaro; G L Cetto; M A Bassetto; M Marangolo
Journal:  Ann Oncol       Date:  1992-12       Impact factor: 32.976

4.  Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.

Authors:  R J Motzer; S C Gulati; W P Tong; C Menendez-Botet; P Lyn; M Mazumdar; V Vlamis; S Lin; G J Bosl
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

5.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.

Authors:  G M Mead; S P Stenning; M C Parkinson; A Horwich; S D Fossa; P M Wilkinson; S B Kaye; E S Newlands; P A Cook
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

6.  Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.

Authors:  E R Broun; C R Nichols; P Kneebone; S D Williams; P J Loehrer; L H Einhorn; G J Tricot
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

7.  High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.

Authors:  C R Nichols; J Andersen; H M Lazarus; H Fisher; J Greer; E A Stadtmauer; P J Loehrer; D L Trump
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

8.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

9.  Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.

Authors:  R N Hitchins; E S Newlands; D B Smith; R H Begent; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

10.  High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours.

Authors:  M J Barnett; C M Coppin; N Murray; T J Nevill; D E Reece; H G Klingemann; J D Shepherd; S H Nantel; H J Sutherland; G L Phillips
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640
View more
  2 in total

1.  Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies.

Authors:  Fausto Petrelli; Andrea Coinu; Giovanni Rosti; Paolo Pedrazzoli; Sandro Barni
Journal:  Med Oncol       Date:  2017-06-26       Impact factor: 3.064

2.  Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.

Authors:  I A McNeish; E J Kanfer; R Haynes; C Giles; S J Harland; D Driver; G J S Rustin; E S Newlands; M J Seckl
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.